Key facts
- It has raised $25.3M; the latest was Early Stage VC ($16.4M) in Apr 2025.
- Notable investors include CDP Venture Capital (Rome), Indaco Venture Partners, Claris Ventures, ENEA Tech Biomedical.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for IAMA Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for IAMA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IAMA Therapeutics
Developer of a neuroscience drug discovery platform designed to provide personalized treatments for patients suffering from untreatable neurological conditions. The company's platform can significantly alleviate the learning and memory difficulties typical of patients with Down syndrome as well as the more significant behavioral manifestations of the autism spectrum, enabling patients to get treatment for their disorders.
- Sector
- Healthcare
- HQ
- Genoa, Italy
- Founded
- 2021
- Employees
- 10
- Website
- iamatherapeutics.com/
- Ownership
- Privately Held (backing)
IAMA Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IAMA Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IAMA Therapeutics in its N-PORT filings yet. We sweep new filings monthly.